Ann Arbor, MI-based NanoBio continues to rack up new, non-dilutive injections of cash to advance its vaccine adjuvant work. The NIH's National Institute of Allergy and Infectious Diseases is giving NanoBio $4.1 million for its work on a project that is developing a nanoscale emulsion adjuvant to boost the efficacy of vaccines. NanoBio is the principal subcontractor for the $9.3 million contract awarded to the University of Michigan.
"NanoBio's nanoemulsion-based vaccine adjuvant platform has consistently demonstrated the ability to elicit robust systemic, cellular and mucosal immunity, based on studies we've conducted in numerous diseases using various antigen types," commented David Peralta, NanoBio's CFO and COO. "This award will fund extensive additional research that will allow NanoBio and the University of Michigan to further advance our adjuvant platform for vaccines."
Boosting the effectiveness of vaccines is considered crucial in mounting a quick response to an outbreak. While Europe has led the way on adjuvants, biotech companies like NanoBio are working on new technology that could help transform the field. The new grant brings its haul of federal money to about $40 million. Last July NanoBio topped off its Series B at $22 million, bringing its total in venture funds to $52 million. The FDA gave NanoBio a green light to start a Phase I trial for its intranasal seasonal flu vaccine earlier this year.
- read the release from NanoBio
- here's the piece from Crain's Detroit Business